NASDAQ:MYOK - Myokardia Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$48.55 +0.60 (+1.25 %)
(As of 06/22/2018 02:49 PM ET)
Previous Close$47.80
Today's Range$47.25 - $49.50
52-Week Range$12.60 - $62.83
Volume19,539 shs
Average Volume455,075 shs
Market Capitalization$1.76 billion
P/E Ratio-34.25
Dividend YieldN/A
Beta3.53
Myokardia logoMyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio4.63
Quick Ratio4.63

Price-To-Earnings

Trailing P/E Ratio-34.25
Forward P/E Ratio-28.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.50 million
Price / Sales77.62
Cash FlowN/A
Price / CashN/A
Book Value$6.76 per share
Price / Book7.18

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-45,950,000.00
Net Margins-235.47%
Return on Equity-25.18%
Return on Assets-20.76%

Miscellaneous

Employees102
Outstanding Shares35,970,000

Myokardia (NASDAQ:MYOK) Frequently Asked Questions

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.21. The biotechnology company earned $5.33 million during the quarter, compared to analysts' expectations of $7.82 million. Myokardia had a negative net margin of 235.47% and a negative return on equity of 25.18%. View Myokardia's Earnings History.

What price target have analysts set for MYOK?

6 equities research analysts have issued 1 year price targets for Myokardia's stock. Their forecasts range from $54.00 to $83.00. On average, they anticipate Myokardia's share price to reach $69.50 in the next twelve months. View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 45)
  • Dr. June Lee, COO & Chief Devel. Officer (Age 52)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 60)
  • Dr. Charles J. Homcy, Advisor (Age 70)
  • Dr. Eric J. Topol, Advisor (Age 64)

Has Myokardia been receiving favorable news coverage?

News headlines about MYOK stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myokardia earned a news impact score of 0.17 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.71 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Myokardia's major shareholders?

Myokardia's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.02%), Farallon Capital Management LLC (2.89%), Foresite Capital Management III LLC (1.09%), Fernwood Investment Management LLC (0.78%), Wells Fargo & Company MN (0.69%) and Northern Trust Corp (0.67%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia.

Which institutional investors are selling Myokardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Citadel Advisors LLC, Iguana Healthcare Management LLC, Eversept Partners LLC and HarbourVest Partners LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for Myokardia.

Which institutional investors are buying Myokardia stock?

MYOK stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Foresite Capital Management III LLC, UBS Group AG, Eventide Asset Management LLC, Victory Capital Management Inc., Hershey Trust Co., Fernwood Investment Management LLC and WINTON GROUP Ltd. Company insiders that have bought Myokardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia.

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $49.45.

How big of a company is Myokardia?

Myokardia has a market capitalization of $1.76 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Myokardia employs 102 workers across the globe.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for Myokardia (MYOK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.